CellMax Life
Liquid biopsy company focused on cancer screening with a proprietary platform for detecting precancer and cancer cells
Liquid biopsy company focused on cancer screening with a proprietary platform for detecting precancer and cancer cells
CellMax Life is a leading cancer diagnostics company that aims to revolutionize cancer diagnosis and management with globally affordable, non-invasive tests for early cancer detection. The company specializes in liquid biopsy and has developed a proprietary platform for detecting pre-cancer and cancer cells. Founded in 2013 and headquartered in the United States, CellMax Life leverages its unique expertise in Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) to develop precision medicine solutions for both healthy individuals and cancer patients.
The company recently attracted significant attention with its Series C investment in 23 March 2021, attracting investment from Artiman Ventures, iD Ventures America, and Aflac Global Ventures. This funding is expected to propel CellMax Life's groundbreaking work in cancer screening and further the development of its innovative diagnostic solutions. With its strong focus on early cancer detection and management, CellMax Life is well-positioned to make a significant impact in the biotechnology and healthcare sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 3 |
|
23 Mar 2021 |
| Series A | $9.00M | 2 |
|
26 Jul 2016 |
| Series A | $5.00M | 1 |
|
01 Jun 2013 |
No recent news or press coverage available for CellMax Life.
We care about your data, and we'd love to use cookies make your experience better.
